[Encellin Inc.] Encellin, Inc. announced a partnership with Breakthrough T1D and an award through its Industry Discovery and Development Partnership program to support the advancement of Encellin’s ENCRT-103-hPI clinical program in T1D.

[Bayer] Bayer announced today that the US FDA has approved Kerendia™ (finerenone), a selective, non-steroidal mineralocorticoid receptor antagonist, for the treatment of adult patients with chronic kidney disease associated with T1D.

[Nature Metabolism] Researchers identified m6A as a central regulator of α-cell state and reveal an epitranscriptomic mechanism controlling endocrine cell plasticity using α-cell and mouse models.

[Diabetologia] The authors performed an in-depth analysis of multiple different small-molecule inhibitors of DYRK1A in human pancreatic islets using gene expression, single-cell RNA-seq, proliferation, immunocytochemistry, and proteomics.

[Diabetes Obesity & Metabolism] Scientists characterized the binding of fluorescently labelled 4hD29 to human islets, human beta cell models and pancreatic tissues from various species over time.

[Iscience] Investigators showed that cytoprotective concentrations of the N-methyl-D-aspartate receptor antagonist dextrorphan upregulate the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) and increase the expression of the pro-apoptotic factor chaC glutathione-specific γ-glutamylcyclotransferase 1 (CHAC1).

[Nature Cancer] The authors identified methylmalonate semialdehyde dehydrogenase (MMSDH), a valine catabolism enzyme, as a driver of gemcitabine resistance in PDAC.

[Cancer Research] Researchers identified protein arginine methyltransferase 1 (PRMT1) as a critical modifier that mediates a metastasis-promoting transcriptional state of SMAD4 in PDAC.

[Proceedings of The National Academy of Sciences of The United States of America] Scientists reported that IRE1α–XBP1s is cytotoxic under hypoxic lipid stress, but PDAC cells become dependent on this pathway when Kirsten rat sarcoma viral oncogene homolog (KRAS) signaling is inhibited or resistance develops.

[Pharmacological Research] The authors demonstrated that co-treatment with elesclomol‑CuCl₂ and oxaliplatin synergistically suppresses PDAC cell proliferation, migration and invasion, while triggering robust reactive oxygen species-dependent immunogenic cell death in vitro and in vivo.

[iScience] Researchers established an aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2)-serpin family E member 1 (SERPINE1) axis that orchestrated epithelial-mesenchymal transition and drove metastasis in Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D-mutant PDAC.

[Pharmacological Research] Scientists synthesize epidemiological and mechanistic evidence linking T2D with cancer and evaluate the oncological implications of major antidiabetic therapies.